​

AbCellera Biologics Stock (NASDAQ:ABCL)

ForecastRevenueOwnershipFinancialsChartTranscripts
AbCellera Biologics by TradingView

Previous Close

$5.30

52W Range

$2.75 - $6.79

50D Avg

$4.51

200D Avg

$4.22

Market Cap

$1.55B

Avg Vol (3M)

$6.29M

Beta

1.18

Div Yield

-

ABCL Company Profile

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

596

IPO Date

Dec 11, 2020

Website

ABCL Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Milestone Payments$1.00M$1.50M$1.50M
License$46.92M$1.05M$969.00K
Research Fees$27.21M$26.28M$35.56M
Royalty---

Fiscal year ends in Dec 25 | Currency in USD

ABCL Financial Summary

Dec 25Dec 24Dec 23
Revenue$75.13M$28.83M$38.02M
Operating Income$-217.10M$-314.77M$-237.21M
Net Income$-146.41M$-162.86M$-146.40M
EBITDA$-155.42M$-204.15M$-192.16M
Basic EPS$-0.49$-0.55$-0.51
Diluted EPS$-0.49$-0.55$-0.51

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 26May 12, 26 | 12:00 AM
Q4 25Feb 24, 26 | 5:00 PM
Q3 25Nov 07, 25 | 5:00 PM

Peer Comparison

TickerCompany
PHVSPharvaris N.V.
SIONSionna Therapeutics, Inc.
NUVBNuvation Bio Inc.
XERSXeris Biopharma Holdings, Inc.
SYRESpyre Therapeutics, Inc.
BHVNBiohaven Ltd.
CLDXCelldex Therapeutics, Inc.
VERAVera Therapeutics, Inc.
JANXJanux Therapeutics, Inc.
IMNMImmunome, Inc.